Lindus Health has secured $55 million in Series B funding to accelerate the development of its AI-powered clinical trial platform, marking a significant step in its mission to revolutionize medical research efficiency. The investment round, led by Balderton Capital with participation from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp, positions the company to expand its innovative "anti-CRO" approach.
The funding will support the enhancement of Lindus Health's Citrus™ eClinical platform, which addresses the persistent challenges in the $112 billion contract research organization (CRO) industry. Traditional clinical trials face significant hurdles, with 85% experiencing delays that impede the development of new treatments and drive up healthcare costs.
Since its 2021 launch, Lindus Health has demonstrated the effectiveness of its approach, successfully conducting 42 end-to-end clinical trials and enrolling over 36,000 patients across North America and Europe. The company has established partnerships with healthcare innovators including Aktiia and Pharmanovia.
"The antiquated CRO model is failing the industry and failing patients, with inefficiencies and misaligned incentives propelling costs and causing researchers to stumble before their breakthroughs can reach patients," said Meri Beckwith, co-founder of Lindus Health. "Lindus breaks the cycle by completely reinventing the way clinical trials operate, allowing life science companies to iterate faster."
The company's Citrus™ platform leverages AI and automation to optimize clinical trial processes through multiple innovations. These include predictive study design optimization using historical data, automated central monitoring for streamlined data collection, instant biostatistics for real-time insights, and efficient patient recruitment methods.
By combining proprietary technology with a vertically integrated service delivery model, Lindus Health aims to address the fundamental inefficiencies in traditional clinical research. The platform's comprehensive approach enables faster, more reliable, and more cost-effective clinical trials, potentially accelerating the development of new medical treatments.
The Series B funding will enable Lindus Health to further develop its AI capabilities and expand its technology infrastructure, supporting its mission to transform the clinical trial landscape. This investment reflects growing industry confidence in technology-driven approaches to clinical research and the potential for AI to accelerate medical innovation.
Click here for the original news story.